


OTRaces has applied noise suppression techniques derived from physics and communications technology to biomarker optimization to achieve 90%+ accuracy (predictive power) with cancer blood tests in both prostate and breast cancer validation trials, using unprecedented access to the Tumor Microenvironment (TME), for real time determination of tumor status and stage. This cloud-based software is biomarker and instrumentation-agnostic and has broad potential for multiple uses worldwide, including collaboration agreements with other companies.

Current funding plans target completion of validation trials for prostate cancer at Johns Hopkins and fast-track launch of a TME PCa active surveillance test (in 2018).




Products and Near Term Goals

1) TME Liquid Biopsy™ Prostate Active Surveillance for at Risk Men

- Detecting progression of prostate cancer from quiescent to life-threatening aggressive tumors is an urgent unmet need in Active Surveillance monitoring programs. The OTraces test is indicating 90% plus accuracy in detecting this progression in validation testing conducted so far. Test Launch and Revenue Projected in 2018.
- **Available market for prostate active surveillance in the U.S. is estimated to be \$200 million.**

2) PR Sera DX Test™ for Prostate Cancer -- a New Screening Option for Men

- Predictive power accuracy of 90%+, false positives **7x lower** and false negatives **3x lower** than the current PSA test, achieved in blinded validation trials at Johns Hopkins.
- **Available U.S. market for PCa screening is estimated at \$2 billion (breast cancer ~\$2 billion also).**



TME Biomarker Upsurges by Stage

TME information processed by OTraces can track tumor progression dynamically, providing a longitudinal record of diagnostic results. This graph shows the biomarker (immune) surges in breast cancer, recorded from serum “signature” measurements. Note that Stage 0 tumor formation is strongly recorded in the TME protein actions. This size tumor (<2 mm) is very difficult to see in radiographic images. Note the 200%+ surge in the Cancer Score during this transition. This score is a composite of the input from five biomarkers used in this test.

Note that OTraces’ Cancer Score Surges from 20 to 190 in the Transition from Healthy (-1) to Stage 0 Breast Cancer (Cancer Score is Arbitrary Range and Goes from 0 to 200, 0 to 100 is Healthy, 101 to 200 is Cancer).

TME (OTRaces) versus DNA Liquid Biopsy – Many Differences: A New Liquid Biopsy Opportunity Emerges

CLINICAL			ECONOMIC		
	TME (OTRaces)	DNA		TME (OTRaces)	DNA
Accuracy	90%+	Unknown	Competitors:	None (patented)	30+ companies
Diagnosis	Real time	Prognosis only	Unit Pricing:	< \$100 tumor screening at 80% plus Gross Margin	\$2,000
				\$600 tumor monitoring at 80% plus Gross Margin	Cannot Screen or Monitor
Over-diagnosis risk	Rare	High	Hi-Vol. Screening scalability:	High	None
Biopsy dependent	No	High	Screening Reimbursement Risk	Low	Very High